On October 5, 2022 NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, reported it will present development progress of its main asset, NT-I7 (efineptakin alfa), across five presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) annual meeting, to be held in Boston, November 8-12, 2022 (Press release, NeoImmuneTech, OCT 5, 2022, View Source [SID1234621755]). These include 1 oral presentation, and 4 poster displays.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
NIT presentations at the 2022 SITC (Free SITC Whitepaper) Annual Meeting:
Primary Author
Abstract Title
Presentation Details
Naing, A
NT-I7, a long-acting IL-7, plus
pembrolizumab favors CD8 T-cell
infiltration in liver metastases of heavily pre-treated,
immunologically cold, MSS-colorectal and
pancreatic cancer
• Abstract #657
• Oral presentation
• Session 213: Next-Generation Cytokine Therapy
• Nov 11, 2022, 5:20 pm – 5:35 pm, EST
Campian, J
A phase I/II study evaluating the safety and
efficacy of a novel long-acting interleukin-7,
NT-I7, for patients with newly diagnosed
high-grade gliomas after chemoradiotherapy
• Abstract #624
• Nov 11, 2022
Kang, H
NT-I7 for the treatment of locally recurrent
squamous cell carcinoma of head and neck
undergoing salvage surgery: A clinical trial in
progress.
• Abstract #679
• Nov 10, 2022
Phoon, Y
NT-I7, a novel long-acting interleukin-7,
improves engraftment of patient immune
cells and efficacy of anti-PD-1 therapy in a
preclinical humanized melanoma model
• Abstract #849
• Nov 10, 2022
Lee, S
Redirecting IL-7-induced bystander tumor-
infiltrating lymphocytes by bispecific T-cell
engager augments antitumor response
• Abstract #837
• Nov 10, 2022
About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.